Bleeker W K, Agterberg J, Rigter G, Hack C E, Gool J V
Central Laboratory, The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Dig Dis Sci. 1992 Feb;37(2):280-5. doi: 10.1007/BF01308184.
In the present study we investigated the therapeutic action of antithrombin III (AT III) in taurocholate-induced experimental pancreatitis with high lethality in rats. High-dose AT III treatment greatly improved the survival rate not only when given as pretreatment but also when given 2 hr after induction. No favorable effect on survival rate was observed on administration after 5 hr. Both intravascular and intraperitoneal AT III administration locally restored decreased AT III levels in the peritoneal cavity and increased plasma AT III to supranormal levels. The primary pancreatic insult seemed to be unaffected by the treatment, because neither the rise in plasma lipase nor the development of ascites or the extension of the pancreatic necrosis were diminished. Because heparin pretreatment of the rats was also effective, the mechanism of the beneficial action was probably mediated by inhibition of the proteases of the coagulation cascade, thereby preventing intravascular coagulation in the pancreas and distant organs and subsequent systemic complications. The high efficacy of AT III treatment in this experimental model may stimulate clinical studies evaluating the efficacy of AT III treatment in an early stage of acute pancreatitis.
在本研究中,我们研究了抗凝血酶III(AT III)对牛磺胆酸盐诱导的、具有高致死率的大鼠实验性胰腺炎的治疗作用。高剂量AT III治疗不仅在作为预处理给药时能显著提高存活率,在诱导后2小时给药时也有此效果。在诱导后5小时给药则未观察到对存活率的有利影响。血管内和腹腔内给予AT III均可使腹腔内降低的AT III水平局部恢复,并使血浆AT III升高至超正常水平。原发性胰腺损伤似乎未受该治疗影响,因为血浆脂肪酶升高、腹水形成或胰腺坏死范围均未减小。由于对大鼠进行肝素预处理也有效,其有益作用机制可能是通过抑制凝血级联反应中的蛋白酶,从而防止胰腺和远处器官内的血管内凝血及随后的全身并发症。AT III治疗在该实验模型中的高效性可能会推动评估AT III治疗在急性胰腺炎早期疗效的临床研究。